CANY
ABMD

Caxton Associates (New York)’s Abiomed Inc ABMD Stock Holding History

Caxton Associates (New York)’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,070
Closed -$512K – 725
2022
Q2 		$512K Buy
2,070
+258
+14% +$69.6K 0.05% 270
2022
Q1 		$600K Buy
+1,812
New +$558K 0.05% 202
2019
Q1 		– Sell
-1,165
Closed -$379K – 515
2018
Q4 		$379K Sell
1,165
-464
-28% -$161K 0.06% 150
2018
Q3 		$733K Sell
1,629
-1,339
-45% -$528K 0.05% 181
2018
Q2 		$1.21M Sell
2,968
-11
-0.4% -$3.98K 0.06% 146
2018
Q1 		$867K Buy
+2,979
New +$755K 0.04% 208

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return

Caxton Associates (New York)'s ABMD Position: Q3 2022 in Review

Caxton Associates (New York) sold out of Abiomed Inc (ABMD) in Q3 2022, closing a stake of 2,070 shares — an estimated $512K sold.

Caxton Associates (New York) first reported a position in ABMD in Q1 2018 and held it in 6 quarters. The position peaked at $1.21M in Q2 2018. 517 funds tracked by Wall St. Rank hold ABMD as of Q3 2022.

  • Caxton Associates (New York) reported no remaining Abiomed Inc position as of Q3 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 2,070 Abiomed Inc shares in Q3 2022, an estimated $512K.
  • Caxton Associates (New York) first reported a position in Abiomed Inc in Q1 2018 and held it in 6 quarters.
  • Caxton Associates (New York)'s Abiomed Inc position peaked at $1.21M in Q2 2018.
  • 517 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2022.

Based on Caxton Associates (New York)'s 13F filing for Q3 2022, filed 14 Nov 2022.